Integrated evidence plan (IEP), an accelerator for drug development and market access
An IEP catalogs all existing and planned evidence, and seeks to identify unmet evidence requirements, dependencies, and common themes across different categories of evidence. Join our panel-discussion with biotech and IQVIA expert-panelists to learn more about IEP and why you should integrate it into your clinical development early on to draw more value from your data. IEP also supports with maximizing the value of your asset and optimizing access to patients.
Our panel draws from the broad experience of leveraging an IEP in biotech’s, we will include early stage biotech start up founders, a biotech CEO with a first product launch, an ISPOR board member discussing the recommendations for evidence gathering and IEPs as well as IQVIA experts that can give examples of how IEPs are leveraged across the industry.
Jennifer Cain Birkmose, Sr. Principal Strategy Consulting, IQVIA AG
Zuzanna Angehrn, PhD, Principal, Real World Solutions, IQVIA AG
Dr. Djordje Filipovic, CEO, AB2 Bio Ltd
Sezai Taskin, Co-Founder, CEO, Moonlight AI
Marlene Gyldmark, Global Head HEOR & Epidemiology, Idorsia Pharmaceuticals Ltd
IQVIA is a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry dedicated to creating intelligent connections that deliver unique and actionable insights. With approximately 86,000 employees, IQVIA conducts operations in more than 100 countries. Learn more at www.iqvia.com.